Ceftriaxone/disodium-edetate/sulbactam - Venus Remedies

Drug Profile

Ceftriaxone/disodium-edetate/sulbactam - Venus Remedies

Alternative Names: Ceftriaxone/EDTA/sulbactam - Venus Remedies; Ceftriaxone/sulbactam/edetic acid fixed dose combination – Venus Remedies; CSE-1034; ELORES; Sulbactomax

Latest Information Update: 09 Sep 2016

Price : $50

At a glance

  • Originator Venus Remedies
  • Class Adjuvants; Antibacterials; Cephalosporins; Ethylenediamines; Penicillins; Small molecules
  • Mechanism of Action Beta lactamase inhibitors; Cell wall inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Nosocomial infections

Most Recent Events

  • 15 Feb 2016 No development reported - Preregistration for Nosocomial infections in USA (IV)
  • 15 Feb 2016 No development reported - Preregistration for Nosocomial infections in Japan (IV)
  • 15 Feb 2016 Preregistration for Nosocomial infections is ongoing in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top